Amanta Healthcare Ltd. వార్షిక వృద్ధి వివరాలు ఆధారంగా కంపెనీ చరిత్ర

Our Company was originally incorporated on December 21, 1994 as Marck Parenterals (India) Limited with RoC, Gujarat, at Ahmedabad by converting the existing Partnership firm “Marck Parenterals (India)” under Part IX of the Companies Act, 1956 and received the Certificate for Commencement of Business on January 06, 1995. The name of our Company was changed to “Marck Biosciences Limited” pursuant to a special resolution passed by our shareholders on October 29, 2005, and a fresh certificate of incorporation issued by the Registrar of Companies, Gujarat, at Ahmedabad, dated November 2, 2005. Subsequently, the name of our Company was changed to “Amanta Healthcare Limited” pursuant to a special resolution passed by our shareholders on June 12, 2014, and a fresh certificate of incorporation dated June 24, 2014 issued by the Registrar of Companies, Gujarat, at Ahmedabad.

Major Events and Milestones:
1994
- Converted in a Public Limited Company

1997
- Started implementation of Large Volume Parenterals (LVP) project for Formulations, Fluid Therapy & Irrigation Solution

1998
- Commencement of L-1 in Block A

2002
- Launched a specialised production line “LVP Line II” for the manufacture of Large Volume Parenterals in Kheda, Gujarat

2005
- Launched a specialised production line “SVP Line I” for the manufacture of Small Volume Parenterals in Kheda, Gujarat.

2007
- Added L-III Large Volume Parenterals Facility for 500 ml products in Block -A

2008
- Launched a specialised production line “SVP line II” for the manufacture of Small Volume Parenterals in Kheda, Gujarat.
- Approval from The National Pharmaceutical Control Bureau – Malaysia (a PIC member)

2021
- Launched a specialised production line “SteriPort -Debottlenecking”

2023
- Received WHO- GMP certification for Manufacturing facility at Kheda, Gujarat

2024
- Got CE Mark Certification for Eye Wash Solutions
- Manufacturing out of seven (7) active production lines including SVP and LVP
- Granted permission to manufacture and market the product named Linezolid I.V. injection (Domestic)